Omega-3 supplements may slash cardiac death risk: Meta-analysis

By Stephen Daniells contact

- Last updated on GMT

© iStock
© iStock
Consumption of omega-3 supplements may reduce the risk of cardiac death by an average of 8%, according to results of a new meta-analysis that pooled data from over 70,000 people.

The risk reduction in people who had elevated triglycerides or LDL cholesterol was even higher at 17%, wrote the scientists from Midwest Biomedical Research and the Johns Hopkins University School of Medicine in the Journal of Clinical Lipidology​.

Cardiac death accounts for about two-thirds of all cardiovascular disease deaths in the United States, and 42% globally, each year, according to the Centers for Disease Control and Prevention (CDC).

“It’s important to note that these results align with the conclusions in the recent Science Advisory from the American Heart Association, which states that EPA and DHA omega-3 treatment ‘is reasonable’ for secondary prevention of coronary heart disease and sudden cardiac death,”​ said Midwest Biomedical Research’s Dr Kevin Maki, the study’s lead author.

“One notable feature of EPA and DHA omega-3 supplementation is the low risk associated with its use. Because of the low risk for adverse effects, even a modest benefit is clinically meaningful.”

Enhanced benefits in North America

Commenting independently on the meta-analysis, Bruce Holub, PhD, University Professor Emeritus at the University of Guelph, told us: This updated review indicates that the majority of adults (without or with clinical evidence of atherosclerotic cardiovascular disease) are likely to receive some significant protection against sudden cardiac death via EPA/DHA supplementation at appropriate intakes.

“The benefit of such supplementation is enhanced in regions where the dietary intake of EPA/DHA from fish/seafood is low as in North America (where average intakes are only 110-150 mg/person/day).”​    

“Important”

Omega-3 © iStock winlyrung
A 2017 meta-analysis of 18 RCTs, also funded by GOED, found that EPA and DHA were associated with a statistically significant reduction in coronary heart disease risk in higher risk populations, including a 16% reduction in those with high triglycerides and 14% in those with high LDL cholesterol (Mayo Clinic Proceedings, Vol. 92, pp. 15–29).Image: © iStock/winlyrung

The new meta-analysis is reportedly the first to include cardiac death (also known as “coronary mortality”) as a primary endpoint, and the most comprehensive review of the evidence to date. It was funded by the Global Organization for EPA and DHA Omega-3s (GOED), but the organization was not involved in the design or interpretation of the results.

Dr Harry Rice, GOED’s VP of regulatory and scientific affairs, welcomed the study’s conclusions, stating: “This study is important because it explored the effects of omega-3s on a specific outcome of coronary heart disease.

“A number of studies in recent years have questioned omega-3 benefits in cardiovascular diseases. In order to understand the role omega-3s play in the cardiovascular system, however, research has to focus on a specific disease rather than all cardiovascular outcomes together. This is an important nuance that this meta-analysis helps clarify.”

Analysis details

Pyramid of evidence based medicine
Systematic reviews and meta-analyses sit at the very top of the pyramid of scientific evidence, making them the strongest forms of evidence.

The new meta-analysis pooled data from 14 randomized, controlled trials (RCTs) totaling 71,899 people. The RCTs reviewed were longer than six months in length, and investigated cardiac death as the primary outcome, comparing frequencies of cardiac death events between the omega-3 and control groups. The authors did not review the effects of EPA and DHA consumption from fish on cardiac death risk because no randomized, controlled trials exist. However, data from observational studies on EPA and DHA from fish also support a benefit in risk reduction.

The results showed that, in addition to the statistically significant 8% reduction in cardiac death risk for consumption of EPA and DHA omega-3s in general, the risk of cardiac death decreased by almost 30% for people who utilized higher dosages of more than 1 gram of EPA and DHA per day (see table below).

None of the studies were set up to elucidate the mechanism of action – how ​omega-3s may reduce the risk of cardiac death – but Maki et al note that dosages greater than 1 gram of EPA + DHA per day, “may be are required to produce clinically relevant changes in some of the pathways, such as effects on inflammation and thrombosis.”

The authors concluded: “These results suggest that additional research is warranted to further evaluate the potential risk reduction with [long chain omega-3] supplementation at higher dosages and in higher risk samples. Future RCTs should include evaluation of biomarkers of omega-3 status at baseline and during treatment and should be designed to test specific hypotheses about the mechanisms through which benefits might be produced. Four RCTs evaluating CVD event risk with [long chain omega-3] interventions are ongoing and should provide helpful additional information to guide clinical use of [long chain omega-3] supplementation or drug therapy.”

Source: Journal of Clinical Lipidology
Published online ahead of print, doi: 10.1016/j.jacl.2017.07.010
“Use of supplemental long-chain omega-3 fatty acids and risk for cardiac death: An updated meta-analysis and review of research gaps”
Authors: K.C. Maki et al.

Related news

Related products

show more

Gemini Pharmaceuticals Quality Partnership Program

Gemini Pharmaceuticals Quality Partnership Program

Gemini Pharmaceuticals | 09-Oct-2017 | Technical / White Paper

A Brand Owner/Own Label Distributor is 100% responsible for the quality of their products - not the Contract Manufacturing Organization. This is exactly...

Resveratrol – Revitalizing Cognitive Function

Resveratrol – Revitalizing Cognitive Function

Evolva | 29-Sep-2017 | Technical / White Paper

Cognitive decline is fast becoming the biggest concern of the 65+ population. A population which is set to reach 1.1 billion by 2030*.  · 80% of 60+ take...

Product Cost Reduction Strategies for the Brand Owner

Product Cost Reduction Strategies for the Brand Owner

Gemini Pharmaceuticals | 11-Sep-2017 | Technical / White Paper

Brand Owners are feeling product price pressure from all corners these days. Consumers are demanding more of the products they buy and want them at a lower...

NattoPharma

12 Reasons MenaQ7® is the Superior Vitamin K2

NattoPharma USA, Inc. | 11-Sep-2017 | Data Sheet

Vitamin K2 as MK-7 supplements are truly changing the face of global health, benefiting old and young alike. We know this because NattoPharma has single-handedly...

Related suppliers

1 comment

Kyani products

Posted by Gina Hale,

Can you take any supplients other than Kyani during the day like fish oils or like vitamin C or any aspirins the same day as you take the Ktani taplets?

After a couple weeks of taken Kyani I was feeling a little dizzy. Is that normal? So I stop taken it for awhile, but also ate an expiry date on this maccarone salad, I don't know if that caused the dizziness or what.

Report abuse

Post your comment

We will not publish your email address on the website

These comments have not been moderated. You are encouraged to participate with comments that are relevant to our news stories. You should not post comments that are abusive, threatening, defamatory, misleading or invasive of privacy. For the full terms and conditions for commenting see clause 7 of our Terms and Conditions ‘Participating in Online Communities’. These terms may be updated from time to time, so please read them before posting a comment. Any comment that violates these terms may be removed in its entirety as we do not edit comments. If you wish to complain about a comment please use the "REPORT ABUSE" button or contact the editors.

Follow us

Products

View more

Webinars